{"id":"novel-strategy-aspirin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Gastrointestinal bleeding or ulceration"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-5","effect":"Nausea"},{"rate":"variable","effect":"Increased bleeding risk"},{"rate":"<1","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin acetylates serine residues on COX-1 and COX-2, preventing the synthesis of prostaglandins and thromboxane A2. This reduces platelet activation and aggregation, lowering thrombotic risk, while also providing anti-inflammatory and analgesic effects through inhibition of prostaglandin-mediated inflammation.","oneSentence":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:49.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke)"},{"name":"Acute coronary syndrome"},{"name":"Mild to moderate pain and fever"},{"name":"Inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT07454707","phase":"PHASE3","title":"Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Stroke, Ischemic","enrollment":1204},{"nctId":"NCT04708587","phase":"NA","title":"Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2021-03-23","conditions":"Chronic Kidney Diseases","enrollment":900},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT02520921","phase":"PHASE4","title":"Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-06-13","conditions":"Diabetes Mellitus, Acute Coronary Syndrome, Coronary Artery Disease","enrollment":2484},{"nctId":"NCT06710184","phase":"PHASE4","title":"Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-05-01","conditions":"NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI), Acute Myocardial Infarction (AMI)","enrollment":5076},{"nctId":"NCT06845566","phase":"NA","title":"Formulation of Compensation Based Intervention","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2025-02-01","conditions":"Stroke","enrollment":30},{"nctId":"NCT05353140","phase":"NA","title":"LAAO Versus NOAC in Patients with AF and PCI","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":1386},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT04436978","phase":"PHASE4","title":"What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2023-01-11","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation","enrollment":2000},{"nctId":"NCT03557242","phase":"NA","title":"Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement","status":"UNKNOWN","sponsor":"Medstar Health Research Institute","startDate":"2018-07-05","conditions":"Aortic Stenosis","enrollment":124},{"nctId":"NCT04502017","phase":"PHASE4","title":"Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"Texas Cardiac Arrhythmia Research Foundation","startDate":"2020-08-05","conditions":"Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion","enrollment":360},{"nctId":"NCT02556203","phase":"PHASE3","title":"Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-12-16","conditions":"Transcatheter Aortic Valve Replacement","enrollment":1653},{"nctId":"NCT03224923","phase":"PHASE4","title":"A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2017-08-18","conditions":"Stable Coronary Syndrome, Percutaneous Coronary Intervention, Antiplatelet Therapy","enrollment":5},{"nctId":"NCT02699008","phase":"NA","title":"High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay","status":"COMPLETED","sponsor":"Wuhan Asia Heart Hospital","startDate":"2014-01","conditions":"Acute Coronary Syndrome","enrollment":477},{"nctId":"NCT02310191","phase":"","title":"Correlation Between Laboratory Markers and Origin of New Brain Ischemic Lesions After Carotid Stenting","status":"COMPLETED","sponsor":"University Hospital Ostrava","startDate":"2012-07","conditions":"Carotid Stenosis, Brain Ischemia, Laboratory Problem","enrollment":81},{"nctId":"NCT01267734","phase":"PHASE4","title":"Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2010-06","conditions":"Coronary Heart Disease","enrollment":3750},{"nctId":"NCT01627431","phase":"PHASE4","title":"Residual Platelet Activity In Advanced Peripheral Artery Disease","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2012-07","conditions":"Peripheral Arterial Disease","enrollment":410},{"nctId":"NCT00734123","phase":"PHASE4","title":"Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.","status":"UNKNOWN","sponsor":"Hospital Arnau de Vilanova","startDate":"2008-04","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":2948}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Novel strategy Aspirin","genericName":"Novel strategy Aspirin","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation. Used for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome, Mild to moderate pain and fever.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}